Denali Therapeutics Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
DNLI Nasdaq 2830 www.denalitherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Denali Therapeutics Inc.

Why Denali Therapeutics (DNLI) Is the Biotech Stock with Biggest Upside Potential - Jan 17th, 2025 4:18 pm
Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases - Jan 13th, 2025 1:00 pm
DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation - Jan 9th, 2025 4:20 pm
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) - Jan 8th, 2025 1:00 pm
Denali Therapeutics price target lowered to $32 from $35 at BTIG - Jan 8th, 2025 12:25 pm
These Stocks Moved the Most Today: Nvidia, Micron, Aurora Innovation, Tesla, Carvana, Moderna, Palantir, and More - Jan 7th, 2025 9:33 pm
Denali Reverses Its Fortunes With 'Too Early' Miss In ALS Treatment - Jan 7th, 2025 9:08 pm
Denali's ALS Study Fails to Meet Primary and Secondary Endpoints - Jan 7th, 2025 7:14 pm
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected - Jan 7th, 2025 5:48 pm
Denali Therapeutics’ ALS therapy fails to meet primary endpoint in Phase II/III trial - Jan 7th, 2025 3:13 pm
Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial - Jan 6th, 2025 9:30 pm
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic - Jan 3rd, 2025 6:08 pm
Denali Therapeutics upgraded to Buy from Hold at Stifel - Dec 17th, 2024 11:25 am
Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report? - Dec 6th, 2024 4:31 pm
Denali Starts Dosing in Phase II Parkinson's Disease Study - Dec 6th, 2024 2:48 pm
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease - Dec 5th, 2024 1:00 pm
We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely - Nov 15th, 2024 1:29 pm
Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging - Nov 8th, 2024 3:08 pm
Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights - Nov 6th, 2024 9:01 pm
Analysts Estimate Arcus Biosciences, Inc. (RCUS) to Report a Decline in Earnings: What to Look Out for - Oct 30th, 2024 2:01 pm